Last reviewed · How we verify
Sunitinib Malate + Valproic Acid — Competitive Intelligence Brief
phase 2
Live · refreshed every 30 min
Target snapshot
Sunitinib Malate + Valproic Acid (sunitinib-malate-valproic-acid) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sunitinib Malate + Valproic Acid TARGET | sunitinib-malate-valproic-acid | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sunitinib Malate + Valproic Acid CI watch — RSS
- Sunitinib Malate + Valproic Acid CI watch — Atom
- Sunitinib Malate + Valproic Acid CI watch — JSON
- Sunitinib Malate + Valproic Acid alone — RSS
Cite this brief
Drug Landscape (2026). Sunitinib Malate + Valproic Acid — Competitive Intelligence Brief. https://druglandscape.com/ci/sunitinib-malate-valproic-acid. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing